OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Clinical Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Radiation therapy and associated cardiovascular outcomes in patients with Hodgkin’s lymphoma.	1144
A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS).	826
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and lung cancer metastasis.	819
Clinical outcomes and prognostic factors in epithelial-myoepithelial carcinoma (EMC) of the breast.	708
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamou	581
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.	571
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (¹⁷⁷Lu-PSMA-617) use by US urologists and oncologists.	484
Health state utility assessment for low-grade glioma.	483
Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospect	479
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.	472
Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.	457
5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.	447
Deep learning for 4D modeling of glioblastoma multiforme with tumor treating fields (TTFields) therapy.	434
Portal vein thrombosis in gastrointestinal cancers: Insights into prevalence and prognosis—A nationwide inpatient analysis 2018-2020.	425
Percutaneous cryoablation of breast cancer metastases: Analysis of long-term single center experience, efficacy and outcomes.	390
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.	384
FOLFOX as a therapeutic option in patients with hepatic failure due to liver metastasis of gastrointestinal (GI) system malignancies: A case series.	367
Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.	358
Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.	352
Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.	342
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS^MULTI(ON) inhibitor.	333
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.	324
Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphom	323
Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis.	315
Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.	310

Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology	306
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.	295
A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-	292
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers.	289
Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients	286
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.	279
NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.	275
Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth facto	275
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analy	275
Preference-weighted quality of life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT).	265
A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX	264
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.	263
Feasibility of functional evaluation in older adults with gastroesophageal cancer using fitness trackers.	260
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.	251
Liver steatosis and fibrosis as independent prognostic factors affecting survival in colorectal cancer with liver metastases.	250
Ground-glass opacity showed response to immunotherapy in cancer patients.	247
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.	247
The role of exosomal LINC00853 in gastric cancer progression.	246
Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?	242
The power of glycobiology: Precision of polyp detection using glycoproteomic biomarkers.	238
Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.	237
Assessing disparities in pancreatic cancer outcomes in African Americans.	236
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.	236
Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.	235
Genetic testing of Japanese patients with serrated polyposis syndrome: A multicentric study.	221
Characterizing the rare abdominal neoplasms of peritoneum, retroperitoneum, and overlapping sites of peritoneum and retroperitoneum: A review of NCDB database.	220
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies.	218
Assessing the impact of hypercalcemia of malignancy on clinical outcomes in cancer patients admitted with acute pancreatitis.	217
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.	214
Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.	207
Implementation of a virtual tumor board through VA National TeleOncology service.	206
Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.	206
Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.	204
Efficacy of alpelisib (ALP) + fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2- advanced breast cancer (ABC).	204
Expanding diversity in colorectal cancer studies with a focus on Hispanic and Latino participant enrollment.	200
Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach.	199
Factors associated with delays in care of suspicious lung nodules at an academic medical center.	199
Abemaciclib dose escalation to maintain intensity (ADE-MI).	199
Impact on biomarker documentation in community oncology by optimizing clinical decision support.	197
Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2.	195
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).	194
Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports.	194
Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, P	193
Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis.	192
Breast cancer outcomes and treatment toxicity in geriatric patients compared to other patients at the Cancer Disease Hospital in Zambia.	190
Disparities in incidence and mortality of hematologic cancers in Southeast Asia: A 2020 analysis.	185
NSQIP audit of enhanced recovery after surgery protocols for radical cystectomy.	184
Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA.	183
Financial toxicity (FT), quality of life (QoL), and medication adherence patient-reported outcomes (PROs) in CLL on first-line (1L) oral oncolytics.	183
Incorporating precision oncology in everyday clinical practice: First two years of comprehensive genomic profiling (CGP) testing experience in Croatia.	182

A novel multi-cancer screening approach based on screening objectives, cancer occurrence mechanism, and cost modeling.	180
A phase I/II trial of neoadjuvant pegylated arginine deiminase (ADI-PEG 20) with ifosfamide and radiotherapy in soft tissue sarcomas (STS) of the trunk or extremity.	178
Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market.	177
Efficacy of mammography screening in women aged 40–49 years: An updated systematic review and meta-analysis.	177
Implementation of video assisted point-of-care germline genetic education and testing for patients with peri-diagnostic pancreatic cancer.	175
Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study.	174
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.	171
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.	171
Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer.	171
Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in patients with head and neck cancer (HNSCC).	171
Effect of IL-15 on anti-tumor immune response to radio-immunotherapy through systemic immune activation.	170
Predictors of long-term survival in immune checkpoint inhibitor (ICI)-associated myocarditis.	169
PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice.	169
Effect of war on radiotherapy in Ukraine and how to help.	169
Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.	169
The role of folate receptor-positive circulating tumor cells in the prognosis analysis of esophageal squamous cell carcinomas.	165
Stereotactic radiosurgery in patients with small cell lung cancer and 1-10 brain metastases: A multi-institutional, phase II, prospective clinical trial.	163
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen recep	162
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen recept	160
Feasibility of implementing whole genome sequencing into routine oncology care.	159
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.	158
Relationship between immune-inflammatory markers and clinical features and deepness of tumor response and prognosis of patients with PD-L1 ≥50% metastatic NSCLC receiving first-line immunotherapy.	157
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.	157
Genomic profile in Mexican women with early-stage breast cancer using Mammaprint+Blueprint assay: A retrospective study.	157
Real-world impact of KRAS mutations on clinical outcomes in metastatic colorectal cancer treated with trifluridine-tipiracil in the USA.	157
Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinic	156
COBRA: Assessment of safety and efficacy of ⁶⁴Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.	155
Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE study).	155
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.	155
Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.	153
VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma.	151
Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study.	150
A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.	150
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.	148
Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience.	147
Efficacy and safety of combination therapy with envafolimab and lenvatinib in patients with endometrial cancer after failure of first-line platinum-based therapy.	147
Genomic instability is enriched in localized prostate cancers from men of African ancestry.	145
A universal pipeline to combine spatial transcriptomics, proteomics, and diagnostic H&E assays on a single tissue section to study tissue microenvironment.	144
The microbiome landscape of early-onset colorectal cancer: A systematic review.	143
The influence of access to care on radiation therapy utilization among older women with breast cancer.	142
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.	142
Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.	142
Use of Oncotype vs. Breast Cancer Index (BCI) for extended endocrine therapy decisions: A single center analysis in stage IA hormone receptor positive breast cancer.	140
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice	139
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2.	139
Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis.	137
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.	136
Use of integrated multi-omics analysis to determine antitumor efficacy of donafenib in combination with FADS2 inhibition in hepatocellular carcinoma.	136
Association of CDX2 expression with clinical, pathologic, and molecular features in MSI-H colorectal cancer.	135
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metast	135
Comparison of real-world mortality data among patients with glioblastoma (GBM) and metastatic pancreatic cancer (mPC) treated in the community oncology setting.	135
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).	135
A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers.	134
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms	134
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.	133
Risk of VTE in TNBC treated with neoadjuvant immunotherapy.	130
Does the time-of-day administration of immune checkpoint inhibitors affect efficacy in patients with metastatic renal cell carcinoma? A single-center study.	129
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.	129
Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.	129
Real world experience of bispecific fusion protein in patients with metastatic uveal melanoma: Can we deliver?	127
Oncology-specific Qualified Clinical Data Registry (QCDR) measures to advance cancer care and achieve Merit-Based Incentive Payment System (MIPS) performance.	127
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRAS^G12C inhibitor, in advanced solid tumors.	127
Multiomic characterization to reveal a distinct molecular landscape in young-onset pancreatic cancer.	126
Multicentric retrospective study on the treatment characteristics, efficacy and safety of eribulin in Slovenian patients with breast cancer.	126
Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR)	125
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.	125
Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact.	125
Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC.	124
Quality initiative (QI) to improve molecular testing in newly diagnosed (ND) stage 4 non-small cell lung cancer (NSCLC-4): An Integra Connect (IC) database study.	123
SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.	122
Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC4	122
Predictors of electronic health record (EHR) portal registration and frequency of portal use among patients with cancer prior to engagement in the IMPACT Consortium symptom management trials.	121
The concerning disaggregation of gender disparity and racial disparity investigation at recent ASCO annual meetings.	121
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.	121
Claims-based cardiac monitoring (CM) in patients (Pts) receiving trastuzumab (TZ).	120
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.	119
A pilot intervention to improve health insurance literacy and financial toxicity among recently diagnosed adolescents and young adults with cancer.	119
LUNG cancer: Supportive oncology program development for patients and care partners: A qualitative study.	118
Glypican-3-specific CAR-NKT cells overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma.	118
KRAS mutation detection and cfDNA in liquid biopsy as prognostic factors in pancreatic adenocarcinoma.	118

EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.	117
A mixed-methods study of healthcare provider perspectives on the barriers to enrollment of minority patients on cancer clinical trials.	117
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-	117
Preliminary clinical investigations of high-dose furmonertinib in NSCLC with EGFR Exon 20 insertions (20ins).	117
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.	116
Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).	116
Cross-ancestry polygenic risk score for breast cancer risk assessment.	116
Adult BMI change over time and risk of colorectal adenoma.	113
An observational study of best supportive care with or without oral capecitabine in patients with metastatic gallbladder cancer.	111
A multicenter, case-control study of a novel multi-target fecal DNA test for colorectal cancer detection.	110
Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.	110
Quality of educational YouTube videos related to pancreatic cancer: Analysis of patient-focused and NCI-designated cancer center videos.	110
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.	109
Tumour radiomics as imaging biomarker of tumour response to chemo-radiotherapy in patients with adenocarcinoma of rectum.	109
Factors associated with weekend emergency department visits in patients with GI cancer.	108
Impact of prophylactic laser therapy on mucositis in patients with head and neck cancer (HNC) undergoing radiotherapy in Brazil.	107
Identifying DNA methylation signatures in high-grade serous ovarian cancer: Results vary by control tissue type.	107
Analyzing the effect of treatment modalities on survival in synovial sarcoma.	107
Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II singl	107
Female participation in U.S. oncology clinical trials registered on ClinicalTrials.gov from 2008 to 2020.	106
Risk factors for ED visits and admissions during outpatient chemotherapy in head and neck cancer.	106
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.	106
Satisfaction with and recommendations to improve telehealth visits among adolescents and young adults with cancer during the COVID-19 pandemic.	105
Evaluating the utility of rule OP-35 to define preventability of ED visits for oncology patients at an academic cancer center.	105
Is recent FDA guidance on HRQoL clinical significance a barrier to clinician/patient treatment risk/benefit discussions: An example using EORTC scale endpoints in a randomized, phase 3 trial.	104
Race- and sex-based variation in industry research and general payments to medical oncologists in the United States.	104
Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant met	103
Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration.	103
CD47 expression patterns in thymic epithelial tumors.	102
Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.	102
Targeting genomic instability in extrapulmonary small cell neuroendocrine cancers: A phase II study with ATR inhibitor berzosertib and topotecan.	101
Characterization of patients with metastatic melanoma that relapses following complete metabolic response from anti–PD-1 therapy.	101
Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.	101
Financial distress, health literacy, numeracy, and treatment receipt by race/ethnicity amongst breast cancer survivors.	101
Genomic landscape and clonal evolution between adenocarcinoma and squamous components in adenosquamous carcinoma of the pancreas.	100
Systematic assessment of online health information related to drug therapy for non-small cell lung cancer.	100
Are we providing adequate information? patient-specific clinical trial information at NCI-designated cancer center websites.	100
Utilization and financial coverage of blood based next generation sequencing for solid tumors: A study from Augusta-Georgia.	100
Obesity diabetes and dyslipidemia as determinants of immune checkpoint inhibitors response in non-small cell lung cancer.	99
Variation in survival rates among patients with angiosarcoma based on demographic and socioeconomic factors in academic versus non-academic settings: An NCDB analysis.	99
Multi-modal single-cell profiling of sarcomas from archival tissue reveals mechanisms of resistance to immune checkpoint inhibitors.	98
Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma.	98
Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.	97
Patients with cancer symptom and physical function reporting by caregivers as predictors of adverse clinical outcomes.	97
Polymorphism rs4673 and plasma paraoxonase 1 level for prediction and early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer.	97
Awareness of the link between HPV, cervical cancer, and HPV vaccination: An online survey among Polish women.	97
Risk of second cancers in long term survivors of neuroendocrine tumors of the large intestine.	96
Circulating nucleosomes to identify non-smoker subjects at risk of lung cancer and triage them for low-dose CT scan.	96
Trends in the incidence of early-onset invasive colorectal cancer between 1990 and 2018, stratified by race/ethnicity, gender, and anatomic sub-sites among Pennsylvania residents.	96
Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naïve BRAF-mutant advanced melanoma: A single institution retrospective analysis.	96
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.	95
Correlation between PD-L1 high-expression and EGFR variants in non-small cell lung cancer.	95
Association of enhanced epithelial-mesenchymal transition signature with tumor microenvironment, angiogenesis, and survival in gastric cancer.	94
The prognostic role of sarcopenia and albumin in locally advanced renal cell carcinoma with IVC tumor thrombus.	94
Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.	93
Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer and borderline pancreatic inoperabl	93
Scenery of multilocus inherited neoplasia alleles syndrome (MINAS) in a single Brazilian institution.	93
Beyond gemtuzumab ozogamicin: A systematic review of antibody therapies for acute myeloid leukemia.	93
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.	92
The impact of virtual live education on the competence and knowledge of gynecologists caring for ovarian cancer patients.	92
Clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma.	91
Pan-Cancer analysis of the mutation frequency of genes in DDR pathway in Chinese population.	91
Mutational profiles of sporadic synchronous colorectal cancer.	91
Evaluation of serum vascular endothelial growth factor as a biomarker in Erdheim-Chester disease.	91
A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regi	91
A cross sectional study on female sexual function following pelvic radiotherapy.	91
Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.	90
Associations between genomic instability score (GIS), molecular characterization, and clinical outcomes in high grade serous ovarian cancers (HGSOC).	90
Participation in cancer research in BNSSG, England: A Health Equity Audit 2021.	90
Hereditary cancer screening at an urban safety net hospital.	90
Improving goal concordant care clinician workshops: Do patients benefit?	89
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.	89
Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.	89
Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study.	89
Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.	89
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.	88
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.	88
Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The immunowave study.	88
Pegylated liposomal doxorubicin combined with ifosfamide for advanced soft tissue sarcomas: A phase I dose-escalation study.	87
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.	87
Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.	86
Therapeutic interchange: The cornerstone of cost effectiveness in the Oncology Care Model performance for the U.S. Oncology Network.	86
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.	86
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.	86
Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.	85
Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.	85
Knowledge and use of different breast cancer screening tools among primary care physicians: A cross-sectional study.	85
Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study.	85
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.	85
The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.	85
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.	84
Lack of organization to access cancer treatment in southeast Brazil: Urgent need to change.	84
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.	84
Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population, a national inpatient sample study.	84
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.	84